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Abstract
Background: The epidermal growth factor receptor (EGFR) is usually overexpressed in nasopharyngeal carcinoma
(NPC) and is associated with pathogenesis of NPC. However, the downstream signaling proteins of EGFR in NPC
have not yet been completely understood at the system level. The aim of this study was identify novel
downstream proteins of EGFR signaling pathway in NPC cells.
Results: We analyzed EGFR-regulated phosphoproteome in NPC CNE2 cells using 2D-DIGE and mass spectrometry
analysis after phosphoprotein enrichment. As a result, 33 nonredundant phosphoproteins including five known
EGFR-regulated proteins and twenty-eight novel EGFR-regulated proteins in CNE2 were identified, three differential
phosphoproteins were selectively validated, and two differential phosphoproteins (GSTP1 and GRB2) were showed
interacted with phospho-EGFR. Bioinformatics analysis showed that 32 of 33 identified proteins contain
phosphorylation modification sites, and 17 identified proteins are signaling proteins. GSTP1, one of the EGFR-
regulated proteins, associated with chemoresistance was analyzed. The results showed that GSTP1 could contribute
to paclitaxel resistance in EGF-stimulated CNE2 cells. Furthermore, an EGFR signaling network based on the
identified EGFR-regulated phosphoproteins were constructed using Pathway Studio 5.0 software, which includes
canonical and novel EGFR-regulated proteins and implicates the possible biological roles for those proteins.
Conclusion: The data not only can extend our knowledge of canonical EGFR signaling, but also will be useful to
understand the molecular mechanisms of EGFR in NPC pathogenesis and search therapeutic targets for NPC.
Background
Nasopharyngeal carcinoma (NPC) is one of the most
common malignant tumors in Southern China [1].
Although NPC is a relatively radiosensitive disease,
some of the NPC patients present local recurrences and
distant metastases after radiotherapy due to radioresis-
tance and the majority of these patients surrender recur-
rence and metastasis within 1.5 year after treatment [2].
Hence, development of a specific targeted therapy for
NPC is urgent for improving the patient survival and
prognosis. Uncovering signaling pathway involved in
NPC cancer biology will provide important information
on targeted therapy for this disease.
Overexpression of epidermal growth factor receptor
(EGFR) is common in NPC [3-5], and most NPC cell
lines and about 85% of the Chinese patients with NPC
have moderate to strong expression of EGFR [6,7].
Moreover, overexpression of EGFR in primary tumors
was associated with tumor metastasis, recurrence, and
poor survival in patients with NPC [7,8]. Recent data
have proposed EGFR as a new target for NPC therapy
[9,10]. These studies suggest that EGFR plays a crucial
role in the development and progression of NPC.
EGFR is one of the most studied receptor tyrosine
kinases. The natural ligands EGF and TGF-a bind to
the extracellular domain of EGFR, and activate the
receptor and its downstream signal proteins, ultimately
causing activation or modulation of various cellular
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pathway have been reported [12], and 177 molecules
involved in EGFR signaling pathway are listed in the
Human Protein Reference Database http://www.hprd.
org, but the downstream signaling proteins of EGFR in
NPC have not yet been completely understood at the
system level.
Signaling transduction is regulated by the phosphory-
lation and dephosphorylation of proteins. Phosphopro-
teomics has an advantage for investigating cellular
signaling pathways by simultaneously identifying a num-
ber of phosphoproteins at one experiment, but it also
has a technical challenge because of the low abundance
of phosphoproteins in cells. Therefore, enrichment of
phosphoproteins is necessary before starting a phopho-
proteomic analysis to increase the sensitivity of identify-
ing phosphoproteins. Two-dimensional difference gel
electrophoresis (2D-DIGE) is a quantitative proteomics
approach with great sensitivity and accuracy of quantita-
tion compared to a conventional 2-DE. Using the 2D-
DIGE, different samples prelabeled with mass- and
charge-matched fluorescent cyanine dyes are co-sepa-
rated in the same 2D gel, and an internal standard is
used in every gel, overcoming the problem of intergel
variation in classical 2-DE. Therefore, 2D-DIGE is able
to efficiently provide accurate and reproducible differen-
tial expression values for proteins in two or more biolo-
gical samples [13,14].
To identify EGFR signaling proteins in NPC cells, in
this study quantitative phosphoproteomics based on
phosphate metal affinity chromatography-enriched
phosphorproteins, 2D-DIGE and mass spectrometry
analysis was applied to identify phosphoproteins after
EGFR activation in NPC cells. We identified 33
EGFR-regulated phosphoproteins, and constructed an
EGFR signaling network based on the identified phos-
phoproteins in NPC cells. The functional validation
showed that GSTP1, one of the EGFR-regulated pro-
teins, is involved in paclitaxel resistance in EGF-stimu-
lated CNE2 cells. The data will provide insights into
our understanding of EGFR signaling pathway and may
have implications on target-directed therapeutics for
NPC.
Methods
Cell culture and EGF treatment
NPC cell line CNE2 cells were cultured to 60-70% con-
fluency in DMEM medium supplemented with 10% fetal
bovine serum (Invitrogen) at 37°C, serum-starved for 24
h, and then were stimulated with 30 ng/mL EGF
(Sigma) or mock-treated as a control. In EGFR blocking
experiments, cells were pretreated with 1 μm EGFR tyr-
osine kinase inhibitor PD153035 (Calbiochem), and fol-
lowed by incubation with EGF.
Phosphoprotein enrichment
A phosphoprotein purification kit (BD Biosciences) was
applied to enrich phosphoproteins from EGF-stimulated
or unstimulated CNE2 cells according to the manufac-
turer’s instructions. To validate the efficacy of phospho-
protein enrichment, 40 μg of proteins from total cellular
lysate, elution fraction containing the highly-concen-
trated and purified phosphoproteins, and flow-through
fraction were separated by 6% SDS-PAGE, followed by
Western blotting using anti-phosphotyrosine antibody
(4G10, Upstate). The concentration of the phosphopro-
teins was determined using a 2-D Quantification Kit
(Amersham Biosciences).
Protein labeling
Phosphoproteins from the elution fractions were preci-
pitated using chloroform-methanol as described by
Wessel and Flugge [15], resolubilized in 2D-DIGE sam-
ple buffer (30 mM Tris, 7 M urea, 2 M thiourea, 4%
CHAPS, pH 8.5), and adjusted to pH 8.5. Equal amount
phosphoproteins from six samples (three biological
repeats) were pooled together as the internal standard.
Three EGF-stimulated samples and three EGF-unstimu-
lated samples were randomly labeled with Cy3 or Cy5,
while internal standards were labeled with Cy2, using
200 pmol fluorochrome/25 μg protein (Amersham Bios-
ciences). Labeling reactions were performed on ice in
the dark for 30 min, and then quenched by the addition
of 1 μL 10 mM lysine (Sigma) for 10 min.
2D-DIGE
Cy3- and Cy5-labelled samples (25 μg) from each pair of
EGF-treated and untreated cells were combined before
mixing with 25 μg Cy2-labelled internal standards. An
equal volume of 2 × sample buffer (8 M urea, 130 mM
DTT) was added to the sample and the total volume
was made up to 450 μL with rehydration buffer (8 M
u r e a ,4 %C H A P S ,1 %B i o l y t e ,p H4 - 7 ,1 3m MD T T ) .
The samples were applied to IPG strips [pH 4-7; non-
linear (NL), 24 cm] and focused on an IPGphor (Amer-
sham Biosciences). The focused IPG strips were
equilibrated, and then were transferred to the tops of
12.5% polyacrylamide gels and run for about 7 h, using
low-fluorescence glass plates on an Ettan DALT II sys-
tem (Amersham Biosciences). All electrophoresis proce-
dures were performed in the dark. The biological
triplicate EGF-stimulated and unstimulated cells and the
internal standard were run on three gels as analytic gels.
In addition, we performed another strip in parallel as a
preparative gel for spot pickings, as described above,
except that the IPG strip was loaded with 1000 μgp r o -
teins and the gel was stained with Coomassie brilliant
b l u e .A f t e rS D S - P A G E ,t h et h r e ea n a l y t i cg e l sw e r e
scanned on a Typhoon 9410 scanner (GE Healthcare) at
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Cy2 (488/520 nm), Cy3 (532/580 nm) and Cy5 (633/670
nm), to generate nine protein spot maps.
Image analysis
Images were cropped using ImageQuant TL 2005 soft-
ware (GE Healthcare) from 2D-DIGE gels, and analyzed
using DeCyder 6.5 software (GE Healthcare) according
to the manufacturer’s recommendations. The DeCyder
differential in-gel analysis (DIA) module was used for
pairwise comparisons of each EGF-stimulated and unsti-
mulated cell sample to the internal standard in each gel.
The DeCyder biological variation analysis (BVA) module
was then used to simultaneously match all nine protein-
spot maps and, using the Cy3: Cy2 and Cy5: Cy2 DIA
ratios, to calculate average abundance changes and
paired Student’s t -test p values for the variance of these
ratios for each protein pair across all samples. The dif-
ferential protein spots (ratio ≥ 1.5, p ≤ 0.05) that altered
consistently in all nine protein-spot maps were selected
for identification.
Protein identification by MS
A l lt h ed i f f e r e n t i a lp h o s p h o p r o t e i ns p o t sw e r ee x c i s e d
from stained preparative gels using punch, destained, and
in-gel trypsin digestion was performed as previously
described by us [16]. Briefly, the gel spots were destained
with 100 mM NH4HCO3 in 50% acetonitrile, dried in a
vacuum centrifuge, and incubated in the digestion solu-
tion (40 mM NH4HCO3, 9% acetonitrile, and 20 μg/mL
proteomics grade trypsin) at 37°C for 14-16 h. The
resulted peptides were extracted with 50% acetonitrile/
2.5% TFA, purified with ZipTip C18 column (Millipore)
and mixed with CCA matrix solution[4-hydroxy-a-
cyanocinnamic acid (HCCA; Sigma) in 30% ACN/0.1%
TFA] followed by analysis with Voyager System DE-STR
4307 MALDI-TOF Mass Spectrometer (ABI) to obtain
the peptide mass fingerprint (PMF). The standard pep-
tide mixture was analyzed at the same time to correct the
machine. The parameters of MALDI-TOF were set up as
follows: positive ionreflector mode, accelerating voltage
20 kV, grid voltage 64.5%, mirror voltage ratio 1.12, N2
laser wavelength 337 nm, pulse width 3 ns, the number
of laser shots 50, acquisition mass range 500-3000 Da,
delay 100 ns, and vacuum degree 4 × 10
-7 Torr.
In peptide mass fingerprint map database searching,
Mascot Distiller was used to obtain the monoisotopic
peak list from the raw mass spectrometry files. Peptide
matching and protein searches against the Swiss-Prot
database were performed using the Mascot search
engine http://www.matrixscience.com/ with a mass tol-
erance of ± 50 p.p.m. Protein scores of ≥ 56 (threshold)
indicate identity or extensive homology (P < 0.05) and
were considered significant.
Bioinformatics analysis
To do phosphorylation site prediction of the identified
proteins, we used on-line PhosphoSitePlus™ system
biology resource http://www.phosphosite.org/ and the
Phospho.ELM database http://phospho.elm.eu.org/index.
html for predicting the presence of the phosphorylation
modification sites [17], and PubMed database searching
http://www.ncbi.nlm.nih.gov for comparing with the phos-
phorylated proteins reported in the literature. In addition,
KEGG pathway analysis of the identified proteins was
done in DAVID bioinformatics resources [18,19].
Validation of EGFR signaling phosphoproteins
by IP-Western blotting
Cells were lysed in the lysis buffer containing 150 mM
NaCl, 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1% Tti-
ton X-100, 1% NP-40 supplemented with phosphatase
inhibitor cocktail 1 and 2 (Sigma-Aldrich) at 4°C, and
subsequently centrifuged at 12000 g for 30 min at 4°C.
Total cellular proteins were immunoprecipitated with
protein G Sepharose (Amersham Biosciences), and anti-
target protein antibody overnight at 4°C. Immunocom-
plexes were used for Western blotting. Briefly, proteins
were separated by 7% SDS-PAGE, and transferred to a
PVDF membrane. Blots were blocked with 3% BSA for
1 h at room temperature, and then incubated with pri-
mary antibody, followed by incubation with HRP-conju-
gated secondary antibodies for 1 h at room temperature.
The signal was visualized using ECL detection reagent.
Transient transfection
The cells were transfected with GSTP1 siRNA or con-
trol siRNA (Santa Cruz Biotechnology) according to the
siRNA transfection protocol provided by the manufac-
turer. Briefly, the day before transfection, CNE2 cells
were plated into 6-well plates at the density of 10
5 cells/
mL in DMEM medium containing 10% FBS (Invitrogen).
When the cells were 60-80% confluent, they were trans-
fected with 10 nmol/L of GSTP1 siRNA or control
siRNA in serum-free DMEM medium using Lipofecta-
mine 2000 reagent (Invitrogen). 4 h after the beginning
of the transfection, the medium was replaced with
DMEM medium containing 10% FCS, and continued to
culture the cells for additional 44 h, and then GSTP1
expression level was determined by Western blotting.
Flow cytometry analysis of apoptotic cells after
treatment of paclitaxel and EGF
At the end of the transfection, the cells were incubated
with 30 nM paclitaxel and 30 ng/mL EGF for 48 h, and
cell apoptosis was examined by flow cytometry as pre-
viously described by us [20]. Briefly, cells were har-
vested, fixed with ice-cold 70% ethanol in PBS at -20°C
for 1 h and then centrifuged at 1 500 rpm for 5 min. The
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and 0.05% RNase (Sigma) in 1 mL PBS at 37°C for 30
min, and then centrifuged at 1 500 rpm for 5 min. The
cell pellets were incubated with 40 μg/mL propidium
iodide (Sigma) in 1 mL PBS at room temperature for 30
min. Samples were immediately analyzed by a FACScan
flow cytometry (Becton Dickinson). Apoptosis was evalu-
ated based on the proportion of sub-G1 hypodiploid
cells. Three independent experiments were done.
Analysis of cell viability by MTT after treatment of
paclitaxel and EGF
At the end of the transfection, the cells were incubated
with the different concentrations of paclitaxel and 30
ng/mL EGF for 48 h, and cell viability was examined
u s i n gM T Ta s s a ya sp r e v i o u s l yd e s c r i b e db yu s[ 2 0 ] .
Briefly, 20 μl of 5 mg/mL MTT (Sigma) was added to
each well, and the medium was removed after 4 h of
incubation. 150 μL DMSO (Sigma) was added to each
well for 10 min at room temperature. The absorbance
of each well was read with a Bio-Tek Instruments
EL310 Microplate Autoreader at 490 nm. Three inde-
pendent experiments were done.
Network modeling
To construct EGFR signaling network (biological inter-
action network of the proteins) of identified phospho-
proteins, functional and pathway analyses were
performed using Pathway Studio 5.0 software, a tool for
the description of networks and signaling pathways [21].
Results
Enrichment of phosphoproteins in EGF-stimulated and
unstimulated NPC cells
A commercial phosphoprotein enrichment kit based on
phosphate metal affinity chromatography was used to
enrich phosphoproteins from EGF-stimulated and unsti-
mulated NPC CNE2 cells. Typically, the elution fraction
contains highly-concentrated and purified phosphopro-
t e i n s .A ss h o w ni nF i g u r e1 A ,levels of phosphorylated
EGFR in CNE2 reached the high peak 15 min after 30
ng/mL EGF-stimulated cells. Then the total proteins of
cells treated by ng/mL EGF for 15 min were used to
enrich phosphoproteins. As shown in Figure 1B, the elu-
tion fractions contained more phosphoproteins com-
pared with the total cellular proteins and flow-through
fractions, indicating that the elution fractions can be
used to identify EGFR-regulated phosphoproteins.
Identification of differential phosphoproteins
in EGF-stimulated and unstimulated NPC cells
by 2D-DIGE and MS
2D-DIGE and MS analysis were performed to identify
differential phosphoproteins in EGF-stimulated and
unstimulated (control) CNE2 cells. As shown in Figure
2A, phosphoproteins were labeled with either Cy3
(EGF-stimulated cells) or Cy5 (control) fluorescent dyes,
while internal standards were labeled with Cy2. The
interchangeable use of either Cy3 or Cy5 for each
experiment has already been established. After 2D-
DIGE, the Cy2, Cy3 and Cy5 images were scanned and
analyzed using DeCyder software. 38 protein spots were
differentially expressed in all nine protein-spot maps
(Figure 2B left); 33 nonredundant proteins were identi-
fied by MS (Table 1); among them, five proteins are
known EGFR-regulated proteins (KRT8, hnRNPK,
KRT18, GRB2, Stathmin), and the other twenty-eight
proteins have not been reported as EGFR-regulated
proteins. A close-up of the region of 2D-DIGE gel
images and a three-dimensional (3D) simulation of spots
22 and 33 significantly up-regulated in EGF-stimulated
cells compared with control are shown in Figure 2B
(right). MALDI-TOF-MS analysis and database match-
ing identified spot 22 as Glutathione S-transferase P 1
(GSTP1) with high sequence coverage and mass accu-
racy (Figure 2C).
Bioinformatics analysis of the identified proteins
Phosphorylation modification sites of 33 identified pro-
teins were analyzed with two online resources (Phospho-
SitePlusTM system biology resource, and the Phospho.
ELM database) to confirm the identified proteins being
phosphoproteins. The results showed that 32 of 33 iden-
tified proteins contain phosphorylation modification sites
except BAG5 (Table 1). In addition, KEGG pathway ana-
lysis showed that 17 identified proteins (HSP7C, KRT8,
T U B B ,V I M ,H S P 6 0 ,P C N A ,R S S A ,C K B ,A T P 5 H ,
STMN1, GSTP1, KRT18, NME1, HSP27, GRB2, PARK7,
a n d3 H I D H )a r es i g n a l i n gp r o t e i n si n v o l v e di nM A P K ,
JAK/STAT and VEGF pathways, etc.. Taken together,
these results support that the proteins identified by pho-
phoproteomics are phosphoproteins.
Validation of identified phosphoproteins
To confirm the results of phosphoproteomics, we
detected the phosphorylated levels of three identified
proteins (ANXA3, KRT8, and KRT18) by IP-Western
blotting. Following immunoprecipitation (IP) of ANXA3,
KRT8, and KRT18 from total cellular proteins, immuno-
complexes were analyzed by Western blotting using anti-
phosphotyrosine antibody. As shown in Figure 3A, the
levels of phosphotyrosine of ANXA3, KRT8, and KRT18
were significantly higher in the 30 ng/mL EGF-stimulated
CNE2 cells than in EGF-unstimulated CNE2 cells, and
tyrosine phosphorylation of ANXA3, KRT8, and KRT18
could be blocked by the pretreatment of the cells with 1
μm EGFR inhibitor PD153035. The results indicate that
EGFR activation can induce phosphorylation of ANXA3,
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phosphoproteomics.
Interaction of identified proteins with phospho-EGFR
IP-Western blotting were performed detect whether
activated (phosphorylated) EGFR interacted with the
two identified phosphoproteins (GSTP1 and GRB2) in
CNE2 cells. As shown in Figure 3B, GSTP1 and GRB2
could be detected in the immunoprecipitation complex
of phospho-EGFR antibody in 30 ng/mL EGF-stimulated
CNE2 cells, and could not be detected by the pretreat-
ment of the cells with 1 μm EGFR inhibitor PD153035,
which indicates that GSTP1 and GRB2 can interact with
phospho-EGFR, are downstream targets of EGFR signal-
ing pathway.
Association of EGFR-regulated GSTP1 with
chemoresistance
To study the functional role of EGFR-regulated GSTP1
in CNE2 cells, CNE2 cells were transfected with GSTP1
siRNA. As shown in Figure 4A, GSTP1 siRNA transfec-
tion knocked down GSTP1 expression in CNE2 cells,
whereas GSTP1 expression was not significantly sup-
pressed by control siRNA. We next evaluated the effects
of GSTP1 siRNA transfection on the paclitaxel sensitiv-
ity in EGF-stimulated CNE2 cells. CNE2 cells trans-
fected with GSTP1 siRNA or control siRNA were
incubated with paclitaxel and EGF for additional 48 h.
And then the cell apoptosis and cell viability were exam-
ined using flow cytometry and MTT assay, respectively.
As Figure 4B and 4C shown, compared with control
Figure 1 Enrichment of phosphoproteins in EGF-stimulated and unstimulated NPC cells. A, Detection of EGFR activation by Western
blotting. CNE-2 cells were stimulated with 30 ng/mL EGF for different times, and Western blotting was performed to detect levels of
phosphorylated EGFR in total cellular proteins. Total EGFR serves as a loading control. B, Enrichment of phosphoproteins. Phosphoprotein
enrichment kit was used to enrich phosphoproteins from total cellular proteins of EGF-stimulated and unstimulated CNE2 cells, and Western
blotting analysis of phosphoproteins using anti-phosphotyrosine antibody(4G10) in the total cellular protein, elution fraction and flow through
fraction. b-actin serves as a loading control.
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Representative 2D-DIGE gel images. Internal standard labeled with Cy2 (a, blue), phosphoproteins from EGF-unstimulated cells labeled with Cy3
(b, green), phosphoproteins from EGF-stimulated cells labeled with Cy5 (c, red), and overlaying Cy3 and Cy5 images (d, yellow). B, (Left) the 38
differential phosphoprotein spots detected by Decyder software; (Right) a close-up of the region of 2D-DIGE gel images and a 3D simulation of
spots 22 and 33. C, MALDI-TOF-MS analysis of differential protein spot 22. Mass spectrum of spot 22 identified as GSTP1 according to the
matched peaks is shown (top). Protein sequence of GSTP1 is shown, and matched peptides are labeled in red letters (bottom).
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and MS
No. Protein name Gene
name
Uniprot
accession
Mw
(Da)
pI Number
of
Matched
Sequence
coverage
Score Ratio
(experiment/
control)
Phosphorylation
sites
peptides (%) Ratio t test
1 Translation endoplasmic reticulam
ATPase (TERA)
VCP P55072 89950 5.14 16 31% 148 1.75 0.0082 Yes
2 Heat shock cognate 71kDa protein HSP7C P11142 71082 5.37 13 38% 118 -1.51 0.018 Yes
3 Keratin,type Ⅱ cytoskeletal 8 KRT8 P05787 53671 5.52 18 43% 139 3.47 0.0035 Yes
4 BAG family molecular chaperone
regulator 5
BAG5 Q9UL15 51738 5.76 4 15% 56 -2.51 0.0001 No
5 TUBB protein TUBB P07437 50095 4.78 25 62% 278 3.12 0.0009 Yes
6 Vimentin VIM P08670 53676 5.06 12 30% 102 1.99 0.0056 Yes
7 Heterogeneous nuclear
ribonucleoprotein K
hnRNPK P61978 51230 5.39 8 31% 86 2.89 0.0005 Yes
8 60KD Heat shock protein HSP60 P10809 61187 5.70 12 29% 109 2.20 0.008 Yes
9 Keratin,type Ⅱ cytoskeletal 8 KRT8 P05787 53671 5.52 6 36% 85 1.63 0.032 Yes
10 Proliferating cell nuclear antigen PCNA P12004 29092 4.57 9 52% 93 2.88 0.0001 Yes
11 F-actin-capping protein subunit
beta
CAPZB P47756 31616 5.36 5 26% 56 2.23 0.009 Yes
12 laminin receptor 1 RSSA P08865 32947 4.79 7 38% 76 1.76 0.0056 Yes
13 Creatine kinase B-type CKB P12277 42902 5.34 7 38% 100 1.99 0.0021 Yes
14 Emerin EMD P50402 28994 5.29 6 21% 77 1.71 0.0014 Yes
15 Heterogeneous nuclear
ribonucleoproteins C1/C2
hnRNP
C1/C2
P07910 33707 4.95 5 18% 68 2.98 0.0008 Yes
16 ATP synthase D chain
mitochondrial
ATP5H O75947 18537 5.21 5 37% 57 2.67 0.005 Yes
17 Prohibitin PHB P35232 29843 5.57 7 37% 120 -2.54 0.031 Yes
18 unidentified 1.79 0.002 N/A
19 Elongation factor 1- delta EEF1D P29692 32.217 4.9 4 25% 72 1.81 0.026 Yes
20 Anamorsin CIAPIN1 Q6FI81 34141 5.44 9 39% 139 2.90 0.0001 Yes
21 Annexin A3 ANXA3 P12429 36524 5.63 7 27% 83 2.83 0.0054 Yes
22 Glutathione S-transferase P1 GSTP1 P09211 23569 5.43 6 34% 97 3.11 0.0013 Yes
23 unidentified 1.64 0.026 N/A
24 Keratin,typeⅠcytoskeletal 18 KRT18 P05783 48029 5.34 13 36% 141 -2.86 0.029 Yes
25 Ran-specific GTPase- activating
protein
RANBP1 P43487 23310 5.71 6 32% 98 1.89 0.034 Yes
26 unidentified 1.68 0.007 N/A
27 Tropomodulin-3 TMOD3 Q9NYL9 39.595 5.08 8 34% 98 2.61 0.003 Yes
28 Myosin light polypeptide 6 MYL6 P60660 17090 4.56 6 50% 70 2.80 0.0019 Yes
29 Nucleoside diphosphate kinase A
(NDKA)
NME1 P15531 17309 5.83 6 48% 105 -1.56 0.0023 Yes
30 Heat shock protein beta-1 HSP27 P04792 22826 5.98 7 47% 84 2.65 0.0001 Yes
31 unidentified -2.72 0.038 N/A
32 Growth factor receptor-bound
protein 2
GRB2 P62993 25,206 5.89 7 39% 75 2.60 0.00028 Yes
33 Glutathione S-transferase P1 GSTP1 P09211 23569 5.43 6 43% 91 3.99 3.2E-06 Yes
34 Peroxiredoxin-2 PRDX2 P32119 22049 5.66 6 54% 98 -1.69 0.042 Yes
35 c-Myc-responsive protein RCL O43598 19211 4.97 4 25% 67 2.25 0.009 Yes
36 Protein DJ-1 PARK7 Q99497 19.891 6.33 5 30% 65 2.99 0.0036 Yes
37 3-Hydroxyisobutyrate
dehydrogenase mitochondrial
precursor (3HIDH)
HIBADH P31937 35705 8.38 4 22% 95 -2.55 0.0051 Yes
38 Stathmin STMN1 P16949 17171 5.77 6 19% 95 2.57 0.0023 Yes
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enhance EGF-stimulated CNE2 cells to paclitaxel sensi-
tivity, with the significant increase of apoptotic cells and
decrease of cell viability, which demonstrates that
EGFR-regulated GSTP1 is involved in chemoresistance
in CNE2 cells.
Construction of EGFR signaling network in NPC cells
Based on the identified phosphoproteins, we constructed
EGFR signaling network using Pathway Studio 5.0 soft-
ware. The result showed that 85% (28/33) proteins
c o u l db en e t w o r k e d( F i g u r e5 ) .T h ep r o t e i n st h a tc o u l d
be networked were linked by various relationships such
as protein binding, protein interactions, modifications
including phosphorylation, and expression regulation.
The biological interaction network has a biological sig-
nificance beyond static phosphoproteome data, suggest-
ing that the majority of the proteins identified in this
study were integral part of the dynamic complex of
EGFR signaling.
Discussion
EGFR play an important role in development, progres-
sion and therapeutic resistance of NPC [6-8], but the
role and mechanisms of EGFR in the NPC are not fully
understood. Activation of EGFR initiates important cell
signaling cascades such as PI3K/AKT/mTOR, JAK/
STAT, and Ras/Raf/MAPK pathways [22]. About 200
targets of EGFR signaling pathway have been reported
[12], and 177 molecules involved in EGFR signaling
pathway are listed in the Human Protein Reference
Database http://www.hprd.org, but EGFR signaling path-
way in NPC still needs to be elucidated.
In the present study, we used quantitative phosphopro-
teomics to identify EGFR-regulated phosphoproteins to
elucidate EGFR signaling pathway in NPC cells at the
system level. 33 proteins were identified in enriched
phosphoproteins from EGFR-activated NPC CNE2 cells,
and three phosphoproteins were validated by IP-Western
blotting. Among the identified proteins, five are known
EGFR signaling proteins and twenty-eight are novel
EGFR signaling proteins. To confirm the phosphopro-
teins identified by phosphoproteomics, online bioinfor-
matics resources were used to predict phosphorylation
sites of 33 identified proteins. The results showed that 32
proteins contain phosphorylation modification sites.
KEGG pathway analysis also showed that 17 identified
proteins are signaling proteins. Taken together,
these results support that the proteins identified by phos-
phoproteomics are phosphoproteins. Interestingly, our
result showed that two identified proteins (GSTP1 and
GRB2) could interact with phospho-EGFR in EGF-stimu-
lated CNE2 cells, further supporting that the identified
phosphoproteins are EGFR signaling proteins.
To uncover the biological context of EGFR signaling
proteins, we constructed a biological interaction network
of the identified phosphoproteins, which has biological
significance beyond static phosphoproteome data. Inter-
estingly, 28 of 33 identified phosphoproteins could be
networked. This strongly suggests that the majority of
the phophoproteins identified in this study were integral
part of the dynamic complex of EGFR signaling. The
proteins that could be networked were linked by various
relationships such as protein binding, protein interac-
tions, modifications including phosphorylation, and
expression regulation. This biological interaction net-
work will be useful for formulating testable hypotheses
to understand the function of novel phosphorylated tar-
gets of EGFR signaling pathway in NPC cells.
GSTP1, a major drug-metabolizing and stress response
signaling protein, belongs to GST family member [23].
Overexpression of GSTP1 has been reported in various
types of human tumors, including colon cancer [24],
gastric cancer [25], esophageal cancer [26], and head
Figure 3 Validation of EGFR-regulated phosphoproteins by IP-
Western blotting. A, IP-Western blotting analysis showing that EGF
induces phosphorylation of three identified proteins (ANXA3, KRT8
and KRT18). Try, anti-phosphotyrosine antibody B, IP-Western blotting
analysis showing that phospho-EGFR interacts with GSTP1 and GRB2.
CBB gel staining serves as loading control (IgG heavy chain).
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human cancer cell chemoresistance [23,28]. Chen
reported that 58% (83/143) primary NPC, 69.8% (30/43)
recurrent NPC, and 65% (13/20) metastatic NPC tissues
highly expressed GSTP1 [29]. Jayasurya reported that all
55 NPC tissues showed positive GSTP1 immunoreactiv-
ity, and a significant correlation was found between
GSTP1 expression and regional nodal metastasis of NPC
[30]. In tumors with EGFR aberrant activation, GSTP1
was phosphorylated and activated, leading to drug inac-
tivation and drug resistance [31]. Our results showed
that activation of EGFR induced GSTP1 phosphorylation
and interaction with EGFR, and GSTP1 is an important
downstream target of EGFR signaling network in NPC
cells. Overexpression of EGFR is frequent in NPC cell
lines and tissues [6,7], and is associated with chemore-
sistance [32]. To explore the effect of EGFR-regulated
GSTP1 in EGFR-induced chemoresistance in NPC cells,
we evaluated the effects of GSTP1 knockdown on the
paclitaxel sensitivity in EGF-stimulated CNE2 cells, and
found that knockdown of GSTP1 expression by siRNA
could increase EGF-stimulated CNE2 cells to paclitaxel
sensitivity. It was obvious that GSTP1 is involved in
EGFR-mediated chemoresistance in NPC cells. Our
findings suggest that in NPC therapy, the double target-
ing of EGFR and GSTP1 could, potentially, be more
effective than the current strategy of targeting either
protein individually.
Figure 4 The effect of GSTP1 siRNA transfection on paclitaxel sensitivity in EGF-stimulated CNE2 cells.A ,W e s t e r nb l o t t i n ga n a l y s i s
showed that transfection of CNE2 cells with GSTP1 siRNA knocked down GSTP1 expression, whereas GSTP1 expression was not significantly
suppressed by control siRNA. B, Flow cytometric analysis showed that GSTP1 siRNA transfection could significantly increase cell apoptosis in
CNE2 cells incubated with paclitaxel and EGF. C, MTT assay showed that GSTP1 siRNA transfection could significantly decrease the cell viability of
CNE2 cells incubated with paclitaxel and EGF. Lipofectamine, cells treated with lipofectmine only.
Ruan et al. Proteome Science 2011, 9:35
http://www.proteomesci.com/content/9/1/35
Page 9 of 11Conclusion
In this study, we identified 33 EGFR signaling proteins
using quantitative phosphoproteomics, constructed an
EGFR signaling network based the identified phospho-
proteins in NPC cells, and validated that GSTP1, one of
the EGFR-regulated proteins, is involved in chemoresis-
tance in NPC cells. The data not only can extend our
knowledge of canonical EGFR signaling, but also will be
useful to understand the molecular mechanisms of
EGFR in NPC pathogenesis and search therapeutic
targets for NPC.
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